AVEO and Schering-Plough to Develop Anti-HGF Antibody
CAMBRIDGE, MassachusettsAVEO Pharmaceuticals, Inc. has entered into an exclusive worldwide agreement with Schering-Plough Corporation to develop and commercialize AV-299, a highly potent antagonist of hepatocyte growth factor/scatter factor (HGF/SF). The antibody has shown excellent efficacy in preclinical models of human cancer and is expected to enter clinical trials in early 2008, the companies announced in a press release.
MammoScreen AI Tool Improves Diagnostic Performance of Radiologists in Detecting Breast Cancer
December 16th 2020This study demonstrated that the concurrent use of this new artificial intelligence tool alongside mammography improved the diagnostic performance of radiologists in the detection of breast cancer without prolonging their workflow.
Preliminary Results Suggest AB-MR Detects Breast Cancers that 3-D Mammograms May Miss
November 29th 2020This study found that abbreviated breast magnetic resonance imaging as a supplemental screening test in women with dense breasts shows an increase in cancer detection over digital breast tomosynthesis screening.
DeepSurv Displays Possible Benefits in Prognostic Evaluation, Treatment Recommendation
July 20th 2020The deep learning survival neural network model demonstrated the potential to provide personalized treatment recommendations based on real clinical data in patients with non-small cell lung cancer.